Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective

References

• Fowkes FJI, Price JF, Fowkes FGC. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 2003;25:1-5
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452-63
   PubMed Web of Science ®Google Scholar
• White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4-18
   PubMed Web of Science ®Google Scholar
• Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (3 Suppl):338S-400S
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines, 8th edn. Chest 2008;133:381S-453S
   PubMedGoogle Scholar
• National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. National Clinical Guideline Centre – Acute and Chronic Conditions. 2010. http://www.nice.org.uk/nicemedia/live/12695/47920/47920.pdf. Accessed March 12, 2011
   Google Scholar
• Blann AD, Lip GY. Venous thromboembolism. BMJ 2006;332:215-9
   PubMedGoogle Scholar
• Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm 2001;58(2 Suppl):S4-13
   PubMedGoogle Scholar
• Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-8
   PubMed Web of Science ®Google Scholar
• Kahn SR. Frequency and determinant of the postthrombotic syndrome after venous thromboembolism. Curr Opin Pulm Med 2006;12:299-303
   PubMed Web of Science ®Google Scholar
• Canadian Joint Replacement Registry. Hip and knee replacements in Canada 2008–2009 Annual Report. Canadian Institute for Health Information. http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=services_cjrr_e. Accessed December 3, 2011
   Google Scholar
• Perzborn E, Kubitza D, Misselwitz F. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie 2007;27:282-9
   PubMedGoogle Scholar
• Graff J, von Hentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007;47:1398-407
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9
   PubMed Web of Science ®Google Scholar
• Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Kakkar AK, Turpie AGG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009;91:636-44
   PubMed Web of Science ®Google Scholar
• Diamantopoulos A, Lees M, Wells PS, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Thromb Haemost 2010;104:760-70
   PubMed Web of Science ®Google Scholar
• Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism even during hospitalization. J Manage Care Pharm 2005;11:663-73
   PubMedGoogle Scholar
• Skedgel C, Goeree R, Pleasance S, et al. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am 2007;89:819-28
   PubMed Web of Science ®Google Scholar
• MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006;63(20 Suppl 6):S5-15
   PubMed Web of Science ®Google Scholar
• Ontario Ministry of Health and Long-Term Care. Government of Ontario, Canada. 2012. https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp. Accessed February 16, 2012
   Google Scholar
• Harrison L, McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158:2001-3
   PubMedGoogle Scholar
• Anonymous. Ontario Association of Community Care Access Centres (OACCAC). 2010
   Google Scholar
• Ontario Case Costing Initiative (OCCI). Acute Inpatient Databases for 2005/06 and 2006/07. Toronto: Ministry of Health and Long-Term Care, 2007
   Google Scholar
• Ontario Schedule of Benefits. Physician Services under the Health Insurance Act (September 1, 2011). Toronto: Ministry of Health and Long-Term Care, 2011
   Google Scholar
• Government of British Columbia. Medical Services Commission Payment Schedule. British Columbia: Government of British Columbia. 2011. http://www.health.gov.bc.ca/msp/infoprac/physbilling/payschedule/index.html Accessed February 16, 2012
   Google Scholar
• Ontario Drug Benefit Formulary 2008. Ministry of Health and Long-Term Care. Toronto: Government of Ontario, Canada, 2008. http://www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html Accessed January 17, 2008
   Google Scholar
• Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003;6:59-74
   PubMed Web of Science ®Google Scholar
• X-RatesTM. http://www.x-rates.com/. Accessed March 17, 2008
   Google Scholar
• Arcelus JI, Monreal M, Caprini JA, et al. Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE Registry. Thromb Haemostat 2008;99:546-51
   PubMed Web of Science ®Google Scholar
• Friedman RJ, Gallus AS, Cushner FD, et al., Global Orthopaedic Registry Investigators. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008;24:87-97
   PubMed Web of Science ®Google Scholar
• Rodger MA, Gagné-Rodger C, Howley HE, et al. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy. Thromb Res 2003;112:13-8
   PubMed Web of Science ®Google Scholar
• Guanella R, Ducruet T, Johri M, et al. Economic burden and cost determinants of deep vein thrombosis during 2 years following diagnosis: a prospective evaluation. J Thromb Haemost 2011;9:2397-405
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Kahn SR, Davidson BL, et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003;21:477-96
   PubMed Web of Science ®Google Scholar
• Gordois A, Posnett J, Borris L, et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 2003;1:2167-74
   PubMed Web of Science ®Google Scholar
• Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost 2007;5:1438-43
   PubMed Web of Science ®Google Scholar
• White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31
   PubMed Web of Science ®Google Scholar
• Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998;129:1044-9
   PubMed Web of Science ®Google Scholar
• Health Canada 2012. Canada’s Health Care System. http://www.hc-sc.gc.ca/hcs-sss/medi-assur/index-eng.php. Accessed March 9, 2012
   Google Scholar
• Statistics Canada. Consumer Price Index, health and personal care, by province. http://www.statcan.ca/english/freepub/62-001-XIE/2007012/tablesectionlist.htm. Accessed 2008
   Google Scholar
• Statistics Canada. Consumer Price Index, health and personal care, by province. http://www40.statcan.gc.ca/l01/cst01/econ161a-eng.htm. Accessed February 16, 2012
   Google Scholar
• Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg 2004;124:507-17
   PubMed Web of Science ®Google Scholar
• Räsänen P, Paavolainen P, Sintonen H, et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop 2007;78:108-15
   PubMed Web of Science ®Google Scholar
• Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc 1997;4:49-56
   PubMed Web of Science ®Google Scholar
• Anderson DR, O’Brien B, Nagpal S, et al. Economic evaluation comparing low molecular weight heparin with other modalities for the prevention of deep vein thrombosis and pulmonary embolism following total hip or knee arthroplasty. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998
   Google Scholar
• Boucher M, Rodger M, Johnson JA, et al. Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care center: a cost minimization analysis. Pharmacotherapy 2003;23:301-9
   PubMed Web of Science ®Google Scholar
• Hooper WC, Evatt BL. The role of activated protein c resistance in the pathogenesis of venous thrombosis. Am J Med Sci 1998;316:120-8
   PubMedGoogle Scholar
• Huo MH, Muntz J. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review. Clin Ther 2009;31:1129-41
   PubMedGoogle Scholar
• Deitelzweig SB, Becker R, Lin J, et al. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism. Thromb Haemost 2008;100:810-20
   PubMed Web of Science ®Google Scholar